Gene modified NK cell line as a powerful tool for evaluation of cloned TCRs for TCR-T cell therapy

Area of Science:

• Immunotherapy
• Cellular Engineering
• Oncology

Background:

• T cell receptor-engineered T cell (TCR-T) therapy shows promise for cancer treatment.
• Current methods for evaluating TCR-induced cytotoxicity using primary T cells are inefficient.
• Advances in TCR isolation allow recognition of diverse peptide-human leukocyte antigen (HLA) complexes.

Purpose of the Study:

• To establish a robust cell line for evaluating TCR-induced cytotoxicity.
• To overcome the limitations of laborious and time-consuming primary T cell assays.
• To create a tool for rapid and efficient assessment of isolated TCR functions.

Main Methods:

• Generation of a T cell receptor (TCR)-negative cell line.
• Transduction of a Natural Killer (NK) cell line with human CD3 and interleukin-2 (IL-2).
• Assessment of cytotoxic activity and cytokine secretion by engineered NK cells.

Main Results:

• The engineered NK cell line effectively killed target cells, similar to TCR-transduced primary T cells.
• The modified NK cells secreted key cytokines and chemokines, including IL-2.
• The established cell line provides homogeneous cell populations for consistent evaluation.

Conclusions:

• Gene-modified NK cells serve as a powerful platform for rapid and efficient TCR function evaluation.
• This approach accelerates the development and validation of TCR-T cell therapies.
• The study offers a scalable solution for assessing TCR-mediated anti-cancer activity.